Try our corporate solution for free!
(212) 419-8286
hadley.ward@statista.com

U.S. and Europe's selected anti-CD19 Car-T therapy sales forecast 2024

By 2024, Yescarta, a Car-T therapy from Gilead Sciences, is expected to have the largest revenue in both regions with 966 million U.S. dollars in the United States and 321 million U.S. dollars in Europe. This statistic shows the estimated 2024 revenues for selected anti-CD19 Car-T therapy in the U.S. and in Europe.

Estimated 2024 revenues of selected anti-CD19 Car-T therapies in the U.S. and in Europe

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

January 2020

Region

Europe, United States

Survey time period

as of January 2020

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Oncology"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.